FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.
What happened
FDA inspected Genuine Virgin Aloe Corp dba Triderma's drug manufacturing facility in Anaheim, CA, from January 17 to 29, 2024. Investigators found the firm did not test incoming ingredients for identity, including glycerin high-risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination, did not validate its manufacturing processes, set three-year expiry dates without stability data, and lacked adequate quality unit oversight. FDA reviewed the firm's February 19, 2024 response and found it inadequate.
What FDA found
The firm did not test each incoming ingredient lot for identity and purity, and relied on supplier certificates without checking they are reliable; glycerin lots were not tested for DEG or EG.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not validate its manufacturing processes and could not show that its equipment was qualified.
21 CFR 211.100(a)The firm assigned three-year expiry dates without stability data showing the products stay acceptable that long.
21 CFR 211.166(a)The quality unit did not oversee records properly; a Psoriasis Control Cream batch record had missing information and annual product reviews were not done per procedure.
21 CFR 211.22(a) and (d)
What FDA wants
FDA asks the firm to respond in writing within 15 working days describing corrections and prevention of recurrence, including DEG/EG test results and a risk assessment for products within expiry by 30 calendar days, and recommends engaging a qualified CGMP consultant.
Who should pay attention
- retailers and brands selling Triderma OTC skin creams
- companies buying glycerin or other high-risk ingredients without identity testing
- contract manufacturers and supplement or drug firms relying on supplier certificates of analysis
This is a summary. Read the original letter on fda.gov.